Tag: Cyclacel Pharmaceuticals

January 28, 2019

Cyclacel Ready for More Clinical Data After Positive 2018

Spiro Rombotis and Paul McBarron of Cyclacel Pharmaceuticals discuss the company's pipeline, indications, clinical data and more.
October 21, 2018

5 Top Weekly NASDAQ Biotech Stocks: MannKind Leads the Pack

MannKind, Sierra Oncology, Eiger BioPharmaceuticals, Aevi Genomic Medicine and KalVista Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology...
October 7, 2018

5 Top Weekly NASDAQ Biotech Stocks: vTv Leads with 374 Percent

vTv Therapeutics, Trevena, Cyclacel Pharmaceuticals, Paratek Pharmaceuticals and Avadel Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index.
September 10, 2018

Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer

Cyclacel Pharmaceuticals (Nasdaq:CYCC, Nasdaq:CYCCP) a biopharmaceutical company developing innovative medicines based on cancer biology, announced the initiation of a Phase...
April 16, 2018

Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

Cyclacel Pharmaceuticals (NASDAQ:CYCC) (NASDAQ:CYCCP) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for...
March 29, 2018

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

Cyclacel Pharmaceuticals (NASDAQ:CYCC) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the...
February 21, 2018

Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations

Cyclacel Pharmaceuticals (NASDAQ:CYCC) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment...